American Cancer Society Institutional Research Grant

  • Davidson, Jeffrey (PI)

Grants and Contracts Details


The ultimate goal of this research is to develop a novel method, termed Sequence Identification of Ligated Oligonucleotides (SILO), which can be exploited for the development of nucleic acid based anti-cancer therapeutics. Traditional therapeutic development requires each potential drug to be tested and analyzed individually, which is time consuming, expensive, and impractical. This work seeks to overcome this problem by developing a novel method, SILO, which can be used to simultaneously test thousands of potential nucleic-acid based drugs for therapeutic activity, including compounds with anti-cancer activity. Using SILO, nucleic acid based compounds from 3 nucleotides on up can be targeted to bind and disrupt disease causing biomolecules at the DNA, RNA, and Protein level. This innovative, combinatorial biotechnology will permit new types of anti-cancer therapeutic compounds to be analyzed, and at a rate much higher than previously possible. The specific aim of this proposal is to develop and optimize the methodology. Preliminary results show that the method does work, however, it is not yet optimal. After optimization, the focus will shift to screening disease targets. Initial studies will concentrate on a target that I am explicitly familiar with: an autocatalytic RNA group I intron that is specific to the opportunistic human pathogen Pneumocystis carinii, which can be lethal to immunocompromised patients, such as those undergoing chemotherapy. This proof of principle data will be used as an initial demonstration of the methodology, and will be of critical importance in seeking extramural funding. SILO will then be exploited for the high-throughput screening of potential anti-cancer therapeutics. Just a few of the multitude of cancer causing targets that can be screened are (1) telomerase, (2) oncogenes such as prostate tumor- inducing gene 1 (PTI-l), and (3) viruses such as human papilloma virus 16 (HPVI6) (cervical cancer).
Effective start/end date7/1/016/30/05


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.